A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

About the trial

Sponsor

BeOne Medicines

Tested

Subcutaneous Tislelizumab (drug), Intravenous Tislelizumab (drug), Cisplatin (drug), Leucovorin (drug), 5-fluorouracil (5-FU) (drug), Oxaliplatin (drug), Capecitabine (drug)

Dates

Started 2025-08-27; completion 2028-04-22

Results posted

Not yet

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines Ltd. reported $734,498 in research payments for this study in 2025 (48 payments).

Products named: Tevimbra

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.